



臺灣新吉美碩股份有限公司
Global Medical Solutions Taiwan, Ltd

11F., No.237, Sec. 1, Fusing S. Rd., Da-an District,
Taipei City 106, Taiwan (R.O.C.)
TEL: (02)2707-9900
FAX: (02)2703-1133

October 16th, 2018

Letter of TRODAT-1 return to Brazilian Market

To whom it may concern,

Global Medical Solutions (GMS) and Grupo RPH (RPH) are pleased to announce that from the second half of October, TRODAT-1 will return to Brazilian Market for the main Nuclear Medicine Centers through RPH distribution.

Since 2013, the radiopharmaceutical TRODAT-1 has been traded in the domestic market, which was originally produced by the Institute of Nuclear Energy Research (INER) in Taiwan.

GMS acquired the global rights to manufacture and distribute TRODAT-1 from INER in 2015, and produces the radiopharmaceutical their contract manufacturer, Shinlin Shinseg Pharmaceutical Co., LTD (SSP).

In June 2018 the manufacturing plant of SSP underwent ANVISA's International Sanitary Inspection in order to obtain the Certificate of Good Manufacturing Practices (GMP).

It's important to point out that TRODAT-1 has continuously been traded by GMS since the acquisition and has not undergone any changes in its formulation. TRODAT-1 continues to maintain the same superior quality characteristics previously known in the Brazilian market. It means that the specifications used for radiochemical purity, product labelling protocol (44 mCi / 5 mL), quality control and image acquisition protocol remain the same as those already validated and used in Brazilian nuclear medicine centers in the past.

GMS has been operating in the Brazilian market for over 15 years and we remain committed to deliver quality and success to the Brazilian Market. While we unfortunately had to take the radiopharmaceutical TRODAT-1 offline in 2017 we are excited to finally bring it back, as we believe it is a product of great relevance for the diagnosis of Parkinson's disease.

With Regards,

Li-Ren Chang
General Manager
Global Medical Solutions Taiwan, Ltd.